Cambian’s failings test investors’ nerve

Care home group must juggle capex without compromising on quality

Small-cap Week, February 13

Cambian, Motive Television, 88 Energy and Cyan in the news

Week in Review

Week in Review, February 13

Asahi, Mylan, Google, Pinewood and European banks in the news

Rush to develop Zika vaccine

Industry response contrasts with slow reaction to Ebola outbreak

Jonathan McHugh illustration
©Jonathan McHugh

NHS isn’t dead but it needs major surgery

Social care is the real illness and that has to be fixed, writes Nicholas Timmins

Exposure: 000 : 00 : 00 . 500 : 500 Binning: 1 x 1 Gain: 5.000000 Accumulated=0

Mini-brains spark drug testing revolution

Aim is to replace animals in pharmaceuticals research

Monitor implant approved for UK diabetics

Latest sign NHS is gradually embracing digital technology

Shield Therapeutics raises £32.5m in Aim debut

Drugmaker on course for market cap of roughly £162m

GSK fined £37m for stifling rival drug

Regulator acts over payments to delay copycat anti-depressants

Mylan defends Meda deal after shares fall

Chief insists takeover will pay off despite high price

Clock ticks on cancer drugs scheme

Replacement sought for £340m-a-year Cancer Drugs Fund

Walgreens threatens to end Theranos tie-up

Blood-testing group told to fix problems at California laboratory

Shire halts $50bn acquisition spree

Drugmaker shifts focus to integrating assets and product launches

Hunt imposes contract on junior doctors

Health secretary targets all doctors below consultant grade

O’Neill ‘superbug’ panel promotes vaccines

Smarter vaccination policy can prevent ‘car crash’ on antibiotics

Mylan in $9.9bn swoop on Sweden’s Meda

Deal is latest to reshape the market for copycat generic drugs

Telecom Plus slips on fuel cost fears

FTSE 100 bounces off a three-year low

Four UK cases of Zika reported this year

Number likely to rise as travellers return from Latin America

Hikma: hik-ups

An unsettling revision to an agreed deal

Hikma reassures over cheaper Roxane deal

UK-listed pharma group renegotiates price for US generics arm of Boehringer Ingelheim


More FT Twitter accounts